eJHaem | |
Anti-SARS-CoV-2 vaccines in recipient and/or donor before allotransplant | |
article | |
Maxime Jullien1  Marianne Coste-Burel2  Beatrice Clemenceau3  Valentin Letailleur1  Thierry Guillaume1  Pierre Peterlin1  Alice Garnier1  Amandine Le Bourgeois1  Berthe-Marie Imbert2  Jocelyn Ollier3  Audrey Grain3  Cyrille Touzeau1  Philippe Moreau1  Marie C Béné3  Henri Vié3  Patrice Chevallier1  | |
[1] Hematology Clinic, Nantes University Hospital;Virology Department, Nantes University Hospital;Inserm 1232, CRCINA, Nantes University;Hematology Biology, Nantes University Hospital | |
关键词: allogeneic; cellular response; COVID-19; hematological; humoral response; SARS-CoV-2 mRNA; vaccine; | |
DOI : 10.1002/jha2.398 | |
来源: Wiley | |
【 摘 要 】
The impact of pre-transplant anti-severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccine in 20 recipients of allogeneic hematopoietic stem cell transplantation (Allo-HSCT) and/or their donors is reported here, showing that the persistence of anti-SARS-CoV-2 antibodies can be detected in almost all patients, whatever the type of vaccine used, and up to 9 months post transplant. Also, an anti-SARS-CoV-2 spike glycoprotein CD3+ T-cell response could be detected in six (35%) of 17 evaluable patients. This study provides a rationale to consider anti-SARS-CoV-2 vaccination of both recipients and donors before Allo-HSCT.
【 授权许可】
Unknown
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO202302050005779ZK.pdf | 237KB | download |